1
Benjamin Oshlack, Mark Chasin: Orally administrable opioid formulations having extended duration of effect. Purdue Pharma, Davidson Davidson and Kappel, October 19, 1999: US05968551 (282 worldwide citation)

Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates includin ...


2
Richard S Sackler, Robert F Kaiko, Paul Goldenheim: Method of treating pain by administering 24 hour oral opioid formulations. Purdue Pharma, Steinberg Raskin & Davidson P C, September 30, 1997: US05672360 (244 worldwide citation)

Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an ...


3
Mark Chasin, Benjamin Oshlack, Frank Pedi Jr: Opioid formulations having extended controlled released. Purdue Pharma, Davidson Davidson & Kappel, September 28, 1999: US05958459 (187 worldwide citation)

Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method of 100 rp ...


4
Richard Sackler, Robert Kaiko, Paul Goldenheim: Method of treating humans with opioid formulations having extended controlled release. Purdue Pharma, Davidson Davidson & Kappel, November 7, 2000: US06143322 (184 worldwide citation)

Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method at 100 rp ...


5
Mark Chasin, Benjamin Oshlack, Frank Pedi Jr: Opioid formulations having extended controlled release. Purdue Pharma, Davidson Davidson & Kappel, August 15, 2000: US06103261 (173 worldwide citation)

Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method of 100 rp ...


6
Benjamin Oshlack, Mark Chasin: Orally administrable opioid formulations having extended duration of effect. Purdue Pharma, Davidson Davidson & Kappel, September 25, 2001: US06294195 (153 worldwide citation)

Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates includin ...


7
Richard Sackler: Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant. Purdue Pharma, Davidson Davidson & Kappel, February 19, 2008: US07332182 (119 worldwide citation)

Disclosed in certain embodiments is an oral dosage form comprising: a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and an irritant in an effective amount to impart an irritating sensation to an abuser upon administration of the dosage form after tampering.


8
Robert F Kaiko, Robert D Colucci: Opioid agonist / antagonist combinations. Purdue Pharma, Davidson Davidson & Kappel, February 6, 2007: US07172767 (102 worldwide citation)

The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is ana ...


9
Benjamin Oshlack, Mark Chasin, Frank Pedi Jr: Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer. Purdue Pharma, Davidson Davidson & Kappel, October 10, 2000: US06129933 (88 worldwide citation)

A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing the coated substrate at a temperature and rel ...


10
Benjamin Oshlack, Frank Pedi: Powder-layered oral dosage forms. Purdue Pharma, Davidson Davidson & Kappel, June 20, 2000: US06077533 (88 worldwide citation)

An oral dosage form of morphine is formulated by powder-layering an homogeneous mixture of morphine sulfate and hydrous lactose impalpable onto inert beads to obtain a multiparticulate product. A plurality of the powder-layered beads may be administered either in immediate release form or in an exte ...